TOTAL BID PRICE Sample Clauses

TOTAL BID PRICE. TOTAL BID PRICE IN FIGURES (as calculated by the Bid Sheet) $ .
AutoNDA by SimpleDocs
TOTAL BID PRICE. A: Subtotal BID Price for one year: $ B: Number of years in the contract: 5 years TOTAL BID PRICE FOR PART II: (A x B): $ Item 2: BID SHEET (PAGE 5 of 8) PIN:15TB023000R0X00 Bidder’s Legal Name: Xxxxxx’s EIN: PART III: NYC PUBLIC HEALTH LABORATORY – Calculation for one year of testing services Enter Bidder’s TEST CODE and TEST SPECIFICATONS, if any. Enter BID PRICE PER TEST (A) and LINE COST (C) for each test specified below. Then enter SUBTOTAL BID PRICE as indicated. A B C TEST CODE DESCRIPTION TEST SPECIFICATION BID PRICE PER TEST ESTIMATED # OF TESTS LINE COST (A*B) Aerobic & anaerobic Culture All [blood, wound, body fluids, tissue] $ 10 $ Antimicrobial susceptibility testing (AST) Included in above $ 10 $ Blood Culture $ 10 $ Neisseria gonorrhea Culture and AST All Sources $ 10 $ Neisseria meningitidis identification, serogrouping, and AST We perform ID and AST - Serogrouping goes to the NYSDOH $ 10 $ B. pertussis culture $ 10 $ H. influenza serotyping We perform ID and AST - Serogrouping goes to the NYSDOH $ 10 $ Listeria monocytogenes serotyping $ 10 $ Legionella Culture, DFA, and Urinary Antigen Test $ 10 $ Mycobacteria Culture, Smear, PCR & AST Reflex to PCR if smear + Send AST to DOH if culture + $ 10 $ Mycobacterial isolate identification & AST Included in above $ 10 $ QuantiFERON – TB Gold (QFT – G) In tube $ 10 $ CT/GC NAAT $ 10 $ Stool Culture $ 10 $ Camphylobacter spp identification Included in Stool Culture $ 10 $ Shiga-toxin-producing E. coli identification and serogrouping Included in Stool Culture - Serogroupingto DOH $ 10 $ Salmonella spp serotyping Included in Stool Culture - Serogroupingto DOH $ 10 $ Shigella spp serotyping and AST Included in Stool Culture - Serogroupingto DOH $ 10 $ Vibrio spp identification Included in Stool Culture $ 10 $ Enteric isolate identification Included in Stool Culture $ 10 $ Norovirus real-time RT-PCR $ 10 $ HIV Viral Load $ 10 $ Multi Spot HIV-1 and HIV-2 $ 10 $ HIV-1 Western Blot Not performed $ 10 $ HIV-2 EIA Not Done - Part ofMultispot above $ 10 $ HIV-2 DNA PCR Same as HIV Viral Load above $ 10 $ HIV pooled NAAT Not Done - DOH Lab $ 10 $ 4th Generation HIV Assay p24 Ag EIA $ 10 $ Hepatitis screen ABC (Hep A Ab, BsAg, BsAb, BcAb, Hep C) $ 10 $ Hepatitis A Ab IgG and IgM $ 10 $ Hepatitis B viral load (quantitative DNA PCR) $ 10 $ Hepatitis B Core Antibody, Total $ 10 $ Item 2: BID SHEET (PAGE 6 of 8) PIN:15TB023000R0X00 Bidder’s Legal Name: Xxxxxx’s EIN: PART III: NYC PUBLIC HEALTH LABORATORY – Year 1...

Related to TOTAL BID PRICE

  • BID PRICES 3.1 Bidders must state in the Attribute Section if the bid prices will remain firm for the full contract period; or if the bid prices will be subject to escalation/de-escalation.

  • Sale Price (a) As consideration for the sale of the CEF Assets pursuant to Section 2.1 hereof, the Purchaser shall pay to the applicable Seller on the Closing Date, the CEF Purchase Price for the CEF Assets sold and transferred by such Seller to the Purchaser on the Closing Date. The CEF Purchase Price for the sale of CEF Assets shall be an amount equal to the fair market value thereof as agreed upon by the Purchaser and the applicable Seller prior to such sale.

  • Closing Price Closing Price shall mean the last reported market price for one share of Common Stock, regular way, on the New York Stock Exchange (or any successor exchange or stock market on which such last reported market price is reported) on the day in question. If the exchange is closed on the day on which the Closing Price is to be determined or if there were no sales reported on such date, the Closing Price shall be computed as of the last date preceding such date on which the exchange was open and a sale was reported.

  • Current Market Price (i) For the purpose of any computation hereunder, other than computations made pursuant to Section 11(a)(iii) (Adjustment of Purchase Price; ----------------------------- Number and Kind of Shares or Number of Rights -- Certain Adjustments) the --------------------------------------------- ------------------- Current Market Price per share of Common Stock on any date shall be deemed to be the average of the daily closing prices per share of such Common Stock for the thirty (30) consecutive Trading Days immediately prior to such date, and for purposes of computations made pursuant to Section 11(a)(iii) the Current Market Price per share of Common Stock on any date shall be deemed to be the average of the daily closing prices per share of such Common Stock for the ten (10) consecutive Trading Days immediately following such date; provided, however, -------- ------- that in the event that the Current Market Price per share of the Common Stock is determined during a period following the announcement by the issuer of such Common Stock of (A) a dividend or distribution on such Common Stock payable in shares of such Common Stock or securities convertible into shares of such Common Stock (other than the Rights), or (B) any subdivision, combination or reclassification of such Common Stock and the ex-dividend date for such dividend or distribution, or the record date for such subdivision, combination or reclassification shall not have occurred prior to the commencement of the requisite thirty (30) Trading Day or ten (10) Trading Day period, as set forth above, then, and in each such case, the Current Market Price shall be properly adjusted to take into account ex-dividend trading. The closing price for each Trading Day shall be the last sale price, regular way, or, in case no such sale takes place on such Trading Day, the average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or admitted to trading on the New York Stock Exchange or, if the shares of Common Stock are not listed or admitted to trading on the New York Stock Exchange, as reported in the principal consolidated transaction reporting system with respect to securities listed on the principal national securities exchange on which the shares of Common Stock are listed or admitted to trading or, if the shares of Common Stock are not listed or admitted to trading on any national securities exchange, the last quoted price or, if not so quoted, the average of the high bid and low asked prices in the over-the-counter market, as

  • Market Price as of any date, (i) means the average of the last reported sale prices for the shares of Common Stock on the OTCBB for the five (5) Trading Days immediately preceding such date as reported by Bloomberg, or (ii) if the OTCBB is not the principal trading market for the shares of Common Stock, the average of the last reported sale prices on the principal trading market for the Common Stock during the same period as reported by Bloomberg, or (iii) if market value cannot be calculated as of such date on any of the foregoing bases, the Market Price shall be the fair market value as reasonably determined in good faith by (a) the Board of Directors of the Company or, at the option of a majority-in-interest of the holders of the outstanding Warrants by (b) an independent investment bank of nationally recognized standing in the valuation of businesses similar to the business of the corporation. The manner of determining the Market Price of the Common Stock set forth in the foregoing definition shall apply with respect to any other security in respect of which a determination as to market value must be made hereunder.

  • Nasdaq Quotation The Company agrees to use commercially reasonable efforts to continue the quotation of the Company Common Stock on The Nasdaq Stock Market during the term of this Agreement.

  • Offering Price Shares of any class of the Fund offered for sale by you shall be offered for sale at a price per share (the "offering price") approximately equal to (a) their net asset value (determined in the manner set forth in the Fund's charter documents) plus (b) a sales charge, if any and except to those persons set forth in the then-current prospectus, which shall be the percentage of the offering price of such Shares as set forth in the Fund's then-current prospectus. The offering price, if not an exact multiple of one cent, shall be adjusted to the nearest cent. In addition, Shares of any class of the Fund offered for sale by you may be subject to a contingent deferred sales charge as set forth in the Fund's then-current prospectus. You shall be entitled to receive any sales charge or contingent deferred sales charge in respect of the Shares. Any payments to dealers shall be governed by a separate agreement between you and such dealer and the Fund's then-current prospectus.

  • Current Ratio The Borrower will not permit, as of the last day of any fiscal quarter, its ratio of (i) consolidated current assets (including the unused amount of the total Commitments, but excluding non-cash assets under FAS 133) to (ii) consolidated current liabilities (excluding non-cash obligations under FAS 133 and current maturities under this Agreement) to be less than 1.0 to 1.0.

  • Market Value Adjustment 16 3.07 Transfer of Current Value from the Funds or AG Account ............ 17 3.08 Notice to the Certificate Holder .................................. 18 3.09 Loans ............................................................. 18 3.10 Systematic Withdrawal Option (SWO) ................................ 18 3.11

  • Applicable Price (a) Share purchase payments and redemption orders that result from purchase payments, premium payments, surrenders and other transactions under Contracts (collectively, "Contract transactions") and that LIFE COMPANY receives prior to the close of regular trading on the New York Stock Exchange on a Business Day will be executed at the net asset values of the appropriate Funds next computed after receipt by AVIF or its designated agent of the orders. For purposes of this Section 2.3(a), LIFE COMPANY shall be the designated agent of AVIF for receipt of orders relating to Contract transactions on each Business Day and receipt by such designated agent shall constitute receipt by AVIF; provided that AVIF receives notice of such orders by 9:00 a.m. Central Time on the next following Business Day or such later time as computed in accordance with Section 2.1(b) hereof.

Time is Money Join Law Insider Premium to draft better contracts faster.